Polaryx Therapeutics PLYX
NASDAQ PLYX
$2.14 -0.02 (-0.93%)
At close: Aug 20, 2026 · 4:00 PM EDT

Polaryx Therapeutics (PLYX) Share-based Compensation (2025 - 2026)

Polaryx Therapeutics (PLYX) posted quarterly Share-based Compensation of $467000.0 for Q1 2026, down 89.51% year-over-year from $4.5 million in Q1 2025, and down 93.86% quarter-over-quarter from $7.6 million in Q4 2025.

Polaryx Therapeutics (PLYX) Share-based Compensation (2025 - 2026) Analysis & Trends

Polaryx Therapeutics (PLYX) has reported Share-based Compensation for 2 consecutive years, with $467000.0 the latest figure, recorded in Q1 2026.

  • In Q1 2026, Share-based Compensation fell 89.51% year-over-year to $467000.0; the TTM figure through Dec 2025 stood at $7.6 million (changed N/A YoY), while the FY2025 annual figure was $7.6 million, up 230.43% from the prior year.
  • Share-based Compensation fell to $467000.0 in Q1 2026 per PLYX's latest filing, from $7.6 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $7.6 million in Q4 2025 and bottomed at $467000.0 in Q1 2026.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Stock Comp. (Qtr)
1 Vertex Pharmaceuticals 137.11 Bn 129.26 Bn 2.84 Bn 108.10 Mn
2 Regeneron Pharmaceuticals 84.98 Bn 76.99 Bn 3.93 Bn 243.00 Mn
3 Argenx Se 64.52 Bn 59.33 Bn 1.37 Bn -
4 Moderna 53.23 Bn 48.09 Bn 52.00 Mn 120.00 Mn
5 BeOne Medicines 41.23 Bn 36.14 Bn 1.53 Bn 137.41 Mn
6 Alnylam Pharmaceuticals 30.65 Bn 27.34 Bn 992.69 Mn 86.63 Mn
7 Insmed 27.15 Bn 25.99 Bn 358.27 Mn 41.25 Mn
8 Royalty Pharma 26.98 Bn 26.14 Bn - -
9 BioNTech SE 26.78 Bn 8.39 Bn 668.28 Mn 28.05 Mn
10 Polaryx Therapeutics 102.35 Mn 90.81 Mn - 7.60 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 7.60 Mn
Jun 30, 2026 7.60 Mn
Mar 31, 2026 467,000.00
Mar 31, 2026 467,000.00
Dec 31, 2025 7.60 Mn
Dec 31, 2025 7.60 Mn
Mar 31, 2025 4.45 Mn
Mar 31, 2025 4.45 Mn